EPISODE · Apr 4, 2024 · 11 MIN
Dengue Outbreaks and Advancements in Colon Cancer Screening: Bill Morice, M.D., Ph.D.
from Answers from the Lab · host Mayo Clinic Laboratories
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss current events including dengue outbreaks, new colon cancer screening technology, and insurance coverage of innovative lab tests.Their discussion includes:The surge of dengue cases in Latin America, and best practices for tick and mosquito bite prevention.Advancements in laboratory tests and technology used for colon cancer screening.Issues with insurers paying for new screening technology versus routine screening methods.How laboratorians can help educate physicians and policymakers on how innovative laboratory tests create value for patients and the entire healthcare system.
What this episode covers
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss current events including dengue outbreaks, new colon cancer screening technology, and insurance coverage of innovative lab tests.Their discussion includes:The surge of dengue cases in Latin America, and best practices for tick and mosquito bite prevention.Advancements in laboratory tests and technology used for colon cancer screening.Issues with insurers paying for new screening technology versus routine screening methods.How laboratorians can help educate physicians and policymakers on how innovative laboratory tests create value for patients and the entire healthcare system.
NOW PLAYING
Dengue Outbreaks and Advancements in Colon Cancer Screening: Bill Morice, M.D., Ph.D.
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m